We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App





New Nanomechanical Technique for Fast, One-Step, Immune-Affinity Tests Rapidly Quantifies Transmissibility of COVID-19 Variants

By LabMedica International staff writers
Posted on 14 Oct 2021

A team of researchers has developed a new nanomechanical technique for fast, one-step, immune-affinity tests, which can quantify the immune response induced by different COVID-19 variants in serum. More...

The technique developed by researchers at Trinity College Dublin (Dublin, Ireland) provides a new tool for tracking infection immunity over time and for analysing new vaccine candidates. The team’s specific quantitative assay enables direct classification of variant-binding properties for screening emerging variants. The major advantage of the newly developed technique with respect to (existing, commonly used) ELISA tests is that while it is equally sensitive – with added single amino-acid resolution – and able to directly detect multiple variants by in situ differential analysis, it can also do so in a mere fraction of the time.

The researchers focused on COVID-19 variants of concern and their generated humoral immune response. Humoral immunity is an antibody-mediated response that occurs when foreign material is detected in the body. Given that the COVID-19 virus has developed substantial mutations in the spike protein, this can undermine the efficacy of current vaccines and monoclonal antibody therapies. The new technology developed by team of researchers can assist vaccine development studies in phase 1-3, with focus on comparing protection patterns and analyzing novel vaccine candidates.

“Our measurements match the statistical analysis of, for example, the transmissibility of the alpha-variant that can otherwise only be gained by analyzing the development of the disease proliferation within a population over weeks. We believe that this new technology can improve and speed up the public health guidance process,” said Professor Martin Hegner, Principal Investigator in the Trinity Centre for Research on Adaptive Nanostructures and Nanodevices (CRANN) and Trinity’s School of Physics. “The direct technique greatly simplifies the preparation protocol that in ELISA includes many washings and waiting steps, hence reducing the amount of consumables needed and thus the relative cost. It will therefore be well suited to use in emergency situations.”

Related Links:
Trinity College Dublin 


Gold Member
SARS-CoV-2 Reactive & Non-Reactive Controls
Qnostics SARS-CoV-2 Typing
Online QC Software
Acusera 24•7
Food Allergy Screening ELISA Kit
Allerquant 14G B ELISA
Automated Clinical Chemistry Analyzer
Envoy 500+
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Capillary testing on the Atellica analyzers supports the most common laboratory testing needs (Photo courtesy of Siemens Healthineers)

Siemens Adds CE-Marked Capillary Claims for 24 Assays on Atellica Analyzers

Venous blood draws can be challenging in patients with difficult veins, needle phobia, or limited blood volume, and they can slow collection in busy services. Core laboratories also face pressure to expand... Read more

Immunology

view channel
Image: Graphical Abstract (Morgane Fournier et al., Cell (2026). DOI: 10.1016/j.cell.2026.04.013)

Study Reveals Immune Mechanism Driving Severe COVID-19 Progression

Severe COVID-19 has highlighted gaps in understanding of early antiviral responses, particularly why some patients deteriorate despite timely care. Type I interferons are central to host defense, yet their... Read more

Pathology

view channel
Image: Agilent’s PD-L1 IHC 22C3 pharmDx has received EU certification as a companion diagnostic to identify PD-L1–positive ovarian, fallopian tube, or primary peritoneal carcinoma patients eligible for KEYTRUDA (Photo courtesy of Agilent)

PD-L1 Assay Guides Pembrolizumab Eligibility in Ovarian, Fallopian Tube, and Peritoneal Cancers

Agilent Technologies’ PD-L1 IHC 22C3 pharmDx (Code SK006) has received European Union certification as a companion diagnostic to aid in identifying patients with epithelial ovarian, fallopian tube, or... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.